ClinicalTrials.gg
RecruitingNCT06646341EVIDENCEUpdated Nov 1, 2024

EMVI as a Determinant of Metastasis in Colorectal Cancer

An observational study in Colo-rectal Cancer, sponsored by Imperial College London. Recruiting at 1 site in United Kingdom. Open to participants aged 16 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-11-01.

Sponsored by Imperial College London · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
100
Ages
16 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 107 studies in Colonic Neoplasms with a site in United Kingdom — 16 open to participants now, 25 under way, 6 of them phase 3. Colonic Neoplasms · United Kingdom.

Planned enrollment
12th of 20
100 · median 300
Started
2023
with 7 others
Observational
20 of 107
6 open now
Primary completion
2025-12
later than 8 of 24 live
Registered
103rd of 107
by date
Lead sponsor
6 of 107
Imperial College London

Among the 107 studies in Colonic Neoplasms with a site in United Kingdom, this one is the 12th largest by planned enrollment of the 20 observational ones that give a count, is one of 8 that started in 2023, is one of 20 observational ones, reaches primary completion later than 8 of the 24 other live ones, and was the 103rd registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

16 of the 107 studies in Colonic Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 16 Years to 100 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Colonic Neoplasms with a site in United Kingdom, or all of them as a file.
02

Study summary

Bowel cancer is the fourth most commonly occurring cancer and the second highest cause of cancer deaths in the UK. Despite advances in treatment, over 40% of patients will die within 5 years. This is normally due to spread of the cancer to other organs (called metastases). Much of the current research focuses on use of additional treatments such as radiotherapy and chemotherapy before or after surgery (adjuvant treatment). It is of vital importance that patients who would benefit from adjuvant treatment can be accurately identified. At the moment, the system used locally to do this places emphasis on the presence of affected lymph nodes (glands). This is because doctors believe that cancer spreads to other organs through the lymphatic system. However, recent studies have suggested that this is not the case.

It is believed that cancer spreads to other organs through the blood stream rather than the lymph node system. This research will look at the genetic material in tumours and metastases as well as in areas of blood vessel invasion and lymph nodes. The analysis will allow us to build a 'family tree' of the tumour and allow us to map the pathway by which the tumour spreads. Tissue samples already collected through a patient's routine care will be used for this study. If the spread through the blood vessels is proven, this would change the way in which patients are selected for treatment and allow development of new treatments to target these pathways.

Read the detailed description

A retrospective ,non-interventional tissue study using archival materials collected through a patient's routine care, EVIDENCE aims to demonstrate that distant metastases in colorectal cancer are related to Extramural Venous Invasion (EMVI) and tumour deposits, not lymph nodes. As EVIDENCE is a retrospective study, there are no time dependent schedules for Case Report Form (CRF) completion or tissue submission.

It will be tested whether the vascular route of spread (as evidenced through EMVI and tumour deposits) is more important than lymph nodes in the development of metastatic disease. The sub-clonal origins of primary colorectal cancers, EMVI, tumour deposits, lymph nodes and distant metastases by reconstructing phylogenetic trees will be compared. A proof for a vascular route of spread rather than lymph nodes would lead to a paradigm shift in future decision making at national and international level.

03

Conditions studied

  • Colo-rectal Cancer

Keywords

  • Extramural Venous Invasion
  • Extranodal Tumour Deposits
  • Imaging and Pathology Biomarkers
  • Pelvic Recurrence
  • Colorectal Cancer
  • Local Advanced Rectal Cancer
  • Metastatic Spread
  • MRI staging
  • Phylogenesis
  • Rectal Cancer Recurrence
  • Sigmoid Cancer
  • Surgery for Pelvic Recurrence
04

Who can participate

Ages eligible
16 Years to 100 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients who have undergone a primary resection of their colon or rectum as well as a resection of a distant metastases

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Are aged 16 years or over with colorectal cancer
  2. Colon / rectum has been surgically removed
  3. Distant has been surgically removed
  4. Pre operative staging in the form of CT/MRI has been undertaken and images available for review

Exclusion criteria

Exclusion Criteria:

  1. Pathological complete response in the primary tumour
  2. Local resection of the primary tumour
  3. Inadequate quantity of tissue sample to perform analyses
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. Comparison of proportion of subjects where Extramural Venous Invasion (EMVI) and tumour deposits vs lymph nodes are associated with distant metastases

    Proportion of subjects where EMVI and tumour deposits rather than lymph nodes are associated with distant metastases. This is to determine the route of spread of distant metastases.

    Time frame: 1 year from last registered patient

Secondary outcomes

  1. Comparison of tumour phylogenetic profile between primary tumour, EMVI, tumour deposits, metastases

    Comparison of tumour phylogenetic profile between primary tumour, EMVI, tumour deposits, metastases. This is to investigate the clonal origins of metastases in relation to the primary tumour deposits, EMVI and lymph nodes

    Time frame: 1 year from last registered patient

  2. Comparison of tumour phylogenes between different metastatic sites and primary tumour

    Comparison of tumour phylogenes between different metastatic sites and primary tumour. This is to determine if there are different routes of spread to different organs (i.e. lung, liver, brain, peritoneal)

    Time frame: 1 year from last registered patient

  3. Comparison of immunohistochemistry staining profile between primary tumour, EMVI, tumour deposits, metastases

    Comparison of immunohistochemistry staining profile between primary tumour, EMVI, tumour deposits, metastases. This is to evaluate the similarities in the immunohistochemistry profile of metastases compared with primary tumour deposits, EMVI and lymph nodes

    Time frame: 1 year from last registered patient

  4. Comparison of overall survival based on clonal origins of metastases

    Comparison of overall survival based on clonal origins of metastases. This is to investigate the relationship between the clonal origins of metastases and outcomes according to primary tumour deposits, EMVI and lymph nodes

    Time frame: 1 year from last registered patient

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2023 (actual). Primary completion is estimated for Dec 2025, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2024
First posted
Oct 17, 2024
StartActual
Jan 1, 2023
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2027
Last update
Nov 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06646341
Responsible party
Sponsor
First posted
Oct 17, 2024
Start date
Jan 1, 2023
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 1, 2024

Study contacts

Caroline Martin
Contact
c.martin1@imperial.ac.uk
+44 (0) 7749 655 817
Syvella Ellis
Contact
syvella.ellis@imperial.ac.uk
+44 (0) 7732 315 234
Gina Brown, MD
principal investigator · Imperial College London

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion